Novo Nordisk

Novo Nordisk strikes second licensing deal since frosty capital-markets day

Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.

Pharma stock soars 150% on injectables deal with Wegovy maker Novo

Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.

After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring

Just days after a capital-markets day left investors wondering what's next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billio…

European drugmakers say they are 'losing ground' to US and Chinese rivals

Some of continent's biggest pharma firms write to national leaders calling for action to safeguard their futures. Some of Europe's biggest pharmaceutical compa…

Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals

Novo Nordisk stock tumbled on Monday as the weight-loss drug manufacturer failed to excite investors hoping for a turnaround.

Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

Is Novo Nordisk AS (NVO) a Bargain After 3.1% Drop? GF Value Says Undervalued

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.

Novo Nordisk (NVO) CEO Advocates for Wegovy Sales Amidst Unregulated Peptide Market

STAT+: Pharmalittle: We're reading about another Novartis trial failure, a Novo Nordisk setback, and more

An experimental Novartis drug for a rare neuromuscular condition failed to improve muscle function in a pivotal study

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Ozempic Maker Novo Nordisk's Investors Are Nervously Looking Into the Future

Novo Nordisk's chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company's…

Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak

While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsch…

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.

Novo Nordisk's raised forecast fails to change the debate over its obesity business

Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.

Novo Nordisk stock is sliding again - and the Wegovy pill's surprise miss is partly to blame

The Danish drugmaker also revealed an improved outlook for the year.

Novo Nordisk shares slide after guidance disappoints investors

Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap.

Ozempic maker Novo Nordisk sues US rival over 'materially misleading' ads

Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effective. Ozempic maker Novo Nordisk said on Tuesday…

Novo Nordisk sues Eli Lilly, accusing it of false advertising

The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.

Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications

The Danish company Novo says U.S.-based Lilly isn't including the most up-to-date clinical information about its drugs.

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

Don't sleep on these medical device leaders.

3 Reasons to Buy Novo Nordisk Stock

The stock is down, but it isn't out yet.

Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant

Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani's NanoPortal platform for chronic weight management. Viva…

Can Novo Nordisk (CPSE:NOVO B) Stay Cheap As GLP 1 Access Expands?

Novo Nordisk stock has pulled back sharply over the past year, yet the shares still screen as undervalued on earnings. This sets up a clear tension between rec…

Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone

Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.

Drugmakers race to find a place in the next wave of obesity drugs

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.